复方黄柏液联合化学药治疗溃疡性结肠炎的Meta分析

Meta-analysis of Compound Huangbo Liquid Combined with Chemical Medicine in the Treatment of Ulcerative Colitis

目的:系统评价复方黄柏液联合化学药治疗溃疡性结肠炎(UC)的疗效和安全性,为临床提供循证参考。方法:计算机检索中国生物医学文献数据库(CBM)、万方数据库、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CJFD)、PubMed、EMBase和Cochrane图书馆,收集复方黄柏液联合化学药(试验组)对比单纯化学药(对照组)治疗UC的随机对照试验(RCT),筛选文献、提取资料并按照Cochrane reviewer’s handbook 5.1.0评价质量后,采用RevMan 5.3统计软件进行Meta分析。结果:共纳入8项RCT,合计737例患者。Meta分析结果显示,试验组患者总有效率显著高于对照组,差异有统计学意义[OR=4.69,95%CI(3.00,7.34),P<0.001];两组患者不良反应发生率比较,差异无统计学意义[OR=0.94,95%CI(0.48,1.84),P=0.86]。结论:复方黄柏液联合化学药治疗UC疗效优于单纯化学药,但两者安全性相当。

OBJECTIVE：To systematically evaluate the clinical efficacy and safety of Compound Huangbo liquid combined with chemical medicine in the treatment of ulcerative colitis（UC）,and to provide evidence-based reference. METHODS：Retrieved from CBM,Wanfang Database,VIP,CJFD,PubMed,EMBase and Cochrane Library,randomized controlled trials（RCTs）about Compound Huangbo liquid combined with chemical medicine（trial group）vs. chemical medicine alone（control group）in the treatment of UC were collected. Meta-analysis was performed by using Rev Man 5.3 statistical sofetware after literature scanning,data extraction and quality evaluation according to Cochrane reviewer＇s handbook 5.1.0. RESULTS：A total of 8 RCTs were included,involving 737 patients. The results of Meta-analysis showed that,response rate of trial group was significantly higher than that of control group,with statistical significance [OR=4.69,95%CI（3.00,7.34）,P〈0.001];there was no statistical significance in the incidence of ADR between 2 groups [OR=0.94,95% CI（0.48,1.84）,P=0.86]. CONCLUSIONS：Compound Huangbo liquid combined with chemical medicine is better than chemical medicine alone for UC,and both have similar safety.